Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT)

NCT06580873 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection
Opioid Use Disorder

Interventions

DRUG: DOVATO

Sponsor

Saskatchewan Health Authority - Regina Area

Collaborators

[object Object]